

## **An Imperfect Science: Antibiotic Tissue Penetration**

### **Will this fluoroquinolone reach the site of infection?**

Anna Seto, Pharm.D.

#### **References**

1. Nix D, Goodwin S, Peloquin C, Rotella D, Schentag J. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. *Antimicrob Agents Chemother* 1991;35(10):1947-52.
2. Owens RJ, Ambrose P. Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. *Diagn Microbiol Infect Dis* 2007;57(3 Suppl):S77-83.
3. Liu P, Derendorf H. Antimicrobial tissue concentrations. *Infect Dis Clin North Am* 2003;17(3):599-613.
4. Bauer LA. *Applied clinical pharmacokinetics*. New York: McGraw-Hill; 2001. 759.
5. Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. *Am J Med* 1993;94(3A):44S-55S.
6. Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? *Rev Infect Dis* 1987;9(4):713-8.
7. Cunha B. Antibiotic pharmacokinetic considerations in pulmonary infections. *Semin Respir Infect* 1991;6(3):168-82.
8. Hidayat L, Hsu D, Quist R, Shriner K, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant *Staphylococcus aureus* infections: efficacy and toxicity. *Arch Intern Med* 2006;166(19):2138-44.
9. Neuman M. Comparative pharmacokinetic parameters of new systemic fluoroquinolones: a review. *Chemioterapia* 1987;6(2):105-12.
10. Rybak M, McGrath B. Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. *Drugs* 1996;52(3):390-405.
11. Michéa-Hamzeshpour M, Pechère J, Marchou B, Auckenthaler R. Combination therapy: a way to limit emergence of resistance? *Am J Med* 1986;80(6B):138-42.
12. Hilf M, Yu V, Sharp J, Zuravleff J, Korvick J, Muder R. Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: outcome correlations in a prospective study of 200 patients. *Am J Med* 1989;87(5):540-6.
13. Cutler N, Vincent J, Jhee S, et al. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. *Antimicrob Agents Chemother* 1997;41(6):1298-300.
14. Wolff M, Boutron L, Singlas E, Clair B, Decazes J, Regnier B. Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis. *Antimicrob Agents Chemother* 1987;31(6):899-902.
15. Lipman J, Allworth A, Wallis S. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. *Clin Infect Dis* 2000;31(5):1131-3.
16. Isaacs D, Slack M, Wilkinson A, Westwood A. Successful treatment of *Pseudomonas ventriculitis* with ciprofloxacin. *J Antimicrob Chemother* 1986;17(4):535-8.

*(continued on next page)*

---

A University of Washington Drug Information Center publication  
Distributed monthly by authority of the Pharmacy and Therapeutics Committee  
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.  
Department of Pharmacy Services / School of Pharmacy

---

Copyright © 2007 by the University of Washington  
Also published at <http://uw.pnrx.org/therapyTopics.asp>  
No material may be reproduced in whole or in part without written permission from the editor.

**References**  
(continued)

17. Wong-Beringer A, Beringer P, Lovett M. Successful treatment of multidrug-resistant *Pseudomonas aeruginosa* meningitis with high-dose ciprofloxacin. *Clin Infect Dis* 1997;25(4):936-7.
18. Morgenroth A, Pfeuffer H, Seelmann R, Schweisfurth H. Pleural penetration of ciprofloxacin in patients with empyema thoracis. *Chest* 1991;100(2):406-9.
19. Stass H, Rink A, Delesen H, Kubitzka D, Vestweber K. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. *J Antimicrob Chemother* 2006;58(3):693-6.
20. Fong I, Ledbetter W, Vandembroucke A, Simbul M, Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. *Antimicrob Agents Chemother* 1986;29(3):405-8.
21. von Baum H, Böttcher S, Abel R, Gerner H, Sonntag H. Tissue and serum concentrations of levofloxacin in orthopaedic patients. *Int J Antimicrob Agents* 2001;18(4):335-40.
22. Malincarne L, Ghebregzabher M, Moretti M, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. *J Antimicrob Chemother* 2006;57(5):950-4.
23. Scotton P, Pea F, Giobbia M, Baraldo M, Vaglia A, Furlanut M. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. *Clin Infect Dis* 2001;33(9):e109-11.
24. Healy D, Holland E, Nordlund M, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. *Cornea* 2004;23(3):255-63.
25. Cekiç O, Batman C, Yasar U, Basci N, Bozkurt A, Kayaalp S. Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration. *Retina* 1998;18(6):521-5.
26. McCulley J, Caudle D, Aronowicz J, Shine W. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. *Ophthalmology* 2006;113(6):955-9.
27. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. *Retina* 2006;26(2):191-5.
28. Cekiç O, Batman C, Yasar U, Basci N, Bozkurt A, Kayaalp S. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. *Eye* 1999;13 ( Pt 4):555-8.
29. Fiscella R, Nguyen T, Cwik M, et al. Aqueous and vitreous penetration of levofloxacin after oral administration. *Ophthalmology* 1999;106(12):2286-90.
30. Hariprasad S, Shah G, Mieler W, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. *Arch Ophthalmol* 2006;124(2):178-82.
31. Goormans E, Dalhoff A, Kazzaz B, Branolte J. Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. *Chemotherapy* 1986;32(1):7-17.
32. Segev S, Rubinstein E, Shick J, Rabinovitch O, Dolitsky M. Penetration of ciprofloxacin into female pelvic tissues. *Eur J Clin Microbiol* 1986;5(2):207-9.
33. Mertes P, Voiriot P, Dopff C, et al. Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. *Antimicrob Agents Chemother* 1990;34(3):398-401.
34. Dan M, Zuabi T, Quassem C, Rotmensch H. Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. *Antimicrob Agents Chemother* 1992;36(3):677-8.
35. Sambatakou H, Giamarellos-Bourboulis E, Galanakis N, Giamarellou H. Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid. *Int J Antimicrob Agents* 2001;18(5):441-4.

(continued on next page)

**References**  
(continued)

36. Dan M, Serour F, Poch F. Penetration of ciprofloxacin into human peritoneal tissue following a single oral dose of 750 milligrams. *J Chemother* 1992;4(1):27-9.
37. Lockley M, Waldron R, Wise R, Donovan I. Intraperitoneal penetration of ciprofloxacin. *Eur J Clin Microbiol* 1986;5(2):209-10.
38. Grabe M, Forsgren A, Björk T. Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection. *Eur J Clin Microbiol* 1986;5(2):211-2.
39. Bulitta J, Kinzig-Schippers M, Naber CK, et al. Limitations in the use of drug cocktails (DC) to compare the pharmacokinetics (PK) of drugs: ciprofloxacin (CIP) versus levofloxacin (LEV). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Toronto, Canada; 17–20 September 2000.
40. Wagenlehner F, Lunz J, Kees F, Wieland W, Naber K. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. *J Chemother* 2006;18(5):485-9.
41. Cruciani M, Gatti G, Cazzadori A, Concia E. Pharmacokinetics of antimicrobial agents in the respiratory tract. *Zentralbl Bakteriol* 1996;284(1):1-31.
42. Dan M, Torossian K, Weissberg D, Kitzes R. The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration. *Eur J Clin Pharmacol* 1993;44(1):101-2.
43. Gotfried M, Danziger L, Rodvold K. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. *Chest* 2001;119(4):1114-22.
44. Andrews J, Honeybourne D, Jevons G, Brenwald N, Cunningham B, Wise R. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. *J Antimicrob Chemother* 1997;40(4):573-7.
45. Lee L, Sha X, Gotfried M, Howard J, Dix R, Fish D. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. *Pharmacotherapy* 1998;18(1):35-41.
46. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. *J Antimicrob Chemother* 1999;44(6):835-8.
47. Breilh D, Jougon J, Djabarouti S, et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. *J Chemother* 2003;15(6):558-62.
48. Pea F, Marioni G, Pavan F, et al. Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. *Pharmacol Res* 2007;55(1):38-41.
49. Gehanno P, Darantière S, Dubreuil C, et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. *J Antimicrob Chemother* 2002;49(5):821-6.
50. Daschner F, Westenfelder M, Dalhoff A. Penetration of ciprofloxacin into kidney, fat, muscle and skin tissue. *Eur J Clin Microbiol* 1986;5(2):212-3.
51. Chow A, Chen A, Lattime H, et al. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. *J Clin Pharm Ther* 2002;27(2):143-50.
52. Bellmann R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. *Br J Clin Pharmacol* 2004;57(5):563-8.
53. Avelox (moxifloxacin hydrochloride [prescribing information]); Bayer Corporation West Haven, CT: 2005.

*(continued on next page)*

**References**  
(continued)

54. Bosseray A, Leclercq P, Manquat G, Stahl J, Micoud M. Penetration of ciprofloxacin into synovial fluid after oral dosing. *J Antimicrob Chemother* 1992;30(6):874-5.
55. Rimmelé T, Boselli E, Breilh D, et al. Diffusion of levofloxacin into bone and synovial tissues. *J Antimicrob Chemother* 2004;53(3):533-5.
56. Dan M, Keynan O, Feldbrin Z, Poch F. Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens. *Diagn Microbiol Infect Dis* 2004;48(4):283-6.
57. Wagenlehner F, Kinzig-Schippers M, Sörgel F, Weidner W, Naber K. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. *Int J Antimicrob Agents* 2006;28(6):551-9.
58. Stein G, Schooley S. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers. *Int J Antimicrob Agents* 2004;24(2):168-72.
59. Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. *J Antimicrob Chemother* 1990;26 Suppl B:61-7.